Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

$2bn AbbVie Deal Puts I-Mab On Global Immuno-Oncology Map

Safety Of CD47 Asset A Major Attraction?

Executive Summary

In another clear signal that China's innovative drug R&D is coming of age, most global rights to I-Mab's promising early-stage CD47 antibody have been picked up by AbbVie in a deal valued at close to $2bn.

You may also be interested in...



Pfizer To Buy Trillium For $2.26bn In A Hematology Pipeline Play

Pfizer will gain two clinical-stage immuno-oncology assets targeting the SRRPα-CD47 axis that it hopes could reach the market in the 2025-2030 timeframe.

AbbVie U-Turns On Dong-A’s MerTK Program After Development Delays

After apparent long delays in development, AbbVie returns rights to Dong-A's MerTK program, with the South Korean pharma yet to determine the fate of the still preclinical stage assets.

Quick Listen: Scrip’s Five Must-Know Things

Join us for a quick audio roundup of major events in the global biopharma industry over the past week, as reported by Scrip.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC142913

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel